相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment algorithm and prognostic factors for patients with stage I-III carcinoma of the anal canal: a 20-year multicenter study
Diane Bruyere et al.
MODERN PATHOLOGY (2021)
Durable and controlled depletion of neutrophils in mice
Gael Boivin et al.
NATURE COMMUNICATIONS (2020)
Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion
Bin Li et al.
ONCOGENESIS (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Vaishali Aggarwal et al.
BIOMOLECULES (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
HMGB1 Promotes Prostate Cancer Development and Metastasis by Interacting with Brahma-Related Gene 1 and Activating the Akt Signaling Pathway
Dao-Jun Lv et al.
THERANOSTICS (2019)
A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine
Michael Herfs et al.
BRITISH JOURNAL OF CANCER (2018)
Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts
Kwanghee Kim et al.
CLINICAL CANCER RESEARCH (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness
Gilles Rademaker et al.
ONCOGENE (2018)
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2018)
HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect
Sijia He et al.
CELL DEATH & DISEASE (2018)
Innovative methodology for the identification of soluble biomarkers in fresh tissues
Brunella Costanza et al.
Oncotarget (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism
Armando Rojas et al.
TUMOR BIOLOGY (2016)
HMGB1 Enhances Drug Resistance and Promotes In Vivo Tumor Growth of Lung Cancer Cells
Hong Zheng et al.
DNA AND CELL BIOLOGY (2016)
Ethyl pyruvate inhibits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages
Young Min Kim et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion
Stephanie A. Demoulin et al.
ONCOIMMUNOLOGY (2015)
HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells
Stephanie Demoulin et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells
Katherine H. Parker et al.
CANCER RESEARCH (2014)
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
T. Yamazaki et al.
CELL DEATH AND DIFFERENTIATION (2014)
High-mobility group box-1 and its role in angiogenesis
Shuai Yang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation
Ben Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis
Mei Zong et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
HMGB1 in Cancer: Good, Bad, or Both?
Rui Kang et al.
CLINICAL CANCER RESEARCH (2013)
A novel blueprint for 'top down' differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia
Michael Herfs et al.
JOURNAL OF PATHOLOGY (2013)
HMGB1 Promotes Drug Resistance in Osteosarcoma
Jun Huang et al.
CANCER RESEARCH (2012)
S100P-Derived RAGE Antagonistic Peptide Reduces Tumor Growth and Metastasis
Thiruvengadam Arumugam et al.
CLINICAL CANCER RESEARCH (2012)
Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34+ hematopoietic progenitor cells: Use of interleukin-3
Stephanie Demoulin et al.
EXPERIMENTAL HEMATOLOGY (2012)
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases
Wei Yan et al.
HEPATOLOGY (2012)
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release
Emilie Venereau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
被撤回的出版物: Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1) (Publication with Expression of Concern. See vol. 26, 2020) (Retracted article. See vol. 26, 2020)
Huan Yang et al.
MOLECULAR MEDICINE (2012)
HMGB1 in Development and Diseases of the Central Nervous System
Ping Fang et al.
MOLECULAR NEUROBIOLOGY (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Reactive oxygen species in cancer
Geou-Yarh Liou et al.
FREE RADICAL RESEARCH (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release
Huan Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells
Michael Herfs et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis
Shaival H. Dave et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein
Hirotaka Kazama et al.
IMMUNITY (2008)
Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C
Kenji Ikeda
HEPATOLOGY RESEARCH (2007)
Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities
Luca Mollica et al.
CHEMISTRY & BIOLOGY (2007)
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin
De Yang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Increased-expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus
K Popovic et al.
ARTHRITIS AND RHEUMATISM (2005)
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein
JS Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
H Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis
R Pullerits et al.
ARTHRITIS AND RHEUMATISM (2003)
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway
S Gardella et al.
EMBO REPORTS (2002)
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes
U Andersson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
